DNB Bioteknologi A

Equity fund

1 year

Region

USA

Largest region

High

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Fondet er et aksjefond som investerer hovedsakelig i aksjer (verdipapirer som representerer en eierandel i et selskap) notert på børser og regulerte markeder over hele verden, innenfor sektorene bioteknologi, diagnostikk, farmasi, produksjon av farmasøytiske produkter, biologiske legemidler herunder genterapi, og annen helserelatert virksomhet. Det vil også være anledning til å investere innenfor selskaper som har deler av sitt virke tilknyttet helse.

Investment horizon

  • DNB Bioteknologi A is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    04 Jun 2025

  • Start date
    04 May 2020
  • ISIN
    NO0010877707

Risk

  • High (5 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 0,85 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee
  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 98%
    Interest 2%

Portfolio

Shows the fund's largest investments.

  • argenx SE
    7.0%
  • Biomarin Pharmaceutical Inc
    6.3%
  • Vertex Pharmaceuticals Inc
    4.4%
  • Alnylam Pharmaceuticals Inc
    4.3%
  • Neurocrine Biosciences Inc
    4.0%
  • Xenon Pharmaceuticals Inc
    3.7%
  • Amgen Inc
    3.5%
  • Ascendis Pharma AS ADR
    3.3%
  • Exact Sciences Corp
    3.2%
  • Axsome Therapeutics Inc
    3.1%